| Outcome Measures: |
Primary: A composite of major adverse cardiovascular events (MACE) or diabetic microvascular events, The time from the date of randomization to the first occurrence of any of the events or records in A\*\* and B\*\* as defined below. \[\*\*A.Major adverse cardiovascular events (MACEs): (1) Death from cardiovascular causes (2) Non-fatal stroke (3) Non-fatal myocardial infarction (4) Hospitalization due to unstable angina (5) Hospitalization due to heart failure (6) Hospitalization due to peripheral artery disease (7) Coronary or peripheral revascularization \*\*B.Diabetic microvascular events * B1. A composite of kidney events: 1. Death from kidney causes 2. Development of end-stage renal disease 3. Sustained decline in eGFR of 40% or more from baseline 4. Occurrence of marked albuminuria, * B2. A composite of eye events: 1. Blindness due to diabetic retinopathy 2. Surgical treatment of diabetic retinopathy or intravitreal injections\], 6-month, 1-, 2-, 3-, 4-year after enrollment | Secondary: Composite endpoint of cardiorenal events_#1, Time from the date of randomization to the first occurrence of any of the events or histories of A\*\* or B\*\* defined in the protocol. \[\*\*A. Major cardiovascular events : (1) Death from cardiovascular cause, (2) Non-fatal stroke, (3) Non-fatal myocardial infarction, (4) hospitalization due to heart failure; \*\*B. Major Kidney Events: (1) Death from kidney causes, (2) Development of end-stage renal disease, (3) Sustained decline in eGFR of 40% or more from baseline\], 6-month, 1-, 2-, 3-, 4-year after enrollment|Composite endpoint of cardiorenal events_#2, Time from the date of randomization to the first occurrence of any of the events or histories of A \[is equal to the "A" defined in the primary endpoint\] or B \[is equal to the "B1" defined in the primary endpoint\] defined in the protocol., 6-month, 1-, 2-, 3-, 4-year after enrollment|Level of HbA1c (glycated haemoglobin), The level is a crucial indicator for managing Type 2 Diabetes. It is used to assess long-term blood sugar control and the effectiveness of your diabetes management strategies., 6-month, 1-, 2-, 3-, 4-year after enrollment|The proportion of participants who exhibited a weight change (either gain or loss) of 10% or more, 6-month, 1-, 2-, 3-, 4-year after enrollment|Change in waist circumference at each time point from baseline, Abdominal obesity is assessed by measuring waist circumference. Long-term follow-up studies have reported that abdominal obesity increases the risk of type 2 diabetes, cardiovascular disease, and death, even after correction for body mass index (BMI)., 6-month, 1-, 2-, 3-, 4-year after enrollment|Change in estimated glomerular filtration rate (eGFR) from baseline, Glomerular filtration rate (GFR) is a measure of how well your kidneys are functioning. It estimates the amount of blood that pass through the glomeruli (the tiny filters in the kidneys) each minute. Estimated GFR will be calcuated by CKD-EPI formula in this study., 6-month, 1-, 2-, 3-, 4-year after enrollment|Change in lipid panel, Lipid panel: blood total cholesterol, LDL-cholesterol, HDL-cholesterol, Tryglycerides., 6-month, 1-, 2-, 3-, 4-year after enrollment|Change in urine albumin to creatinine ratio (UACR) from baseline, The urine albumin to creatinine ration (UACR) is a test that measures the amount of albumin (a typie of protein) in the urine relative to the amount of creatinine. It is used to assess your kidney function, particularly to detect early signs of kidney damage or disease., 6-month, 1-, 2-, 3-, 4-year after enrollment|Safety endopoints, Incidence rate and charateristics (causality, seriousness, severity, outcomes, action taken etc.) of adverse events, serious adverse events, and adverse events of special interest (acute kidney injury, hypoglycemia, acute hyperglycemic complications, GI symptoms, ,urogenital infection, edema, weight gain), 6-month, 1-, 2-, 3-, 4-year after enrollment
|
